April 30 (Reuters) - Baxter on Thursday beat

Wall Street estimates for first-quarter profit and revenue,

helped by robust sales in its medical products and therapies

unit.

Shares of the Deerfield-Illinois based company rose over

9%in premarket trading following the results.

"Financial results for the quarter overall were in line with

our expectations, and we are making progress to stabilize the

business," said Baxter CEO Andrew Hider.

On an adjusted basis, Baxter earned a profit of 36 cents per

share for the quarter ended March 31, above analysts' estimate

of 31 cents per share, according to LSEG data.

Quarterly revenue came in at $2.70 billion, ahead of

estimates of $2.62 billion.

First-quarter sales at the company's largest business,

medical products and therapies unit, which includes IV

solutions, rose 2% to $1.29 billion from a year ago and

surpassing estimates of $1.23 billion.

Baxter, however, said the division was held back by lower

infusion pump sales after it disclosed a shipment and

installation hold on its Novum IQ Large Volume Pump.

Tariffs and higher manufacturing costs weighed on earnings

in the quarter, the company said, without specifying a dollar

figure for the full-year tariff impact.

"We expect it's too early in the turnaround story for

investors to be swayed more bullish or bearish by one okay

quarter," said J.P.Morgan analyst Robbie Marcus.